Antisense oligonucleotides for cancer therapy - An overview

Lung Cancer

Volumn 41, Issue SUPPL. 1, 2003, Pages 81-88

  Stahel, Rolf A ^a   Zangemeister Wittke, Uwe ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antisense; Cancer; Oligonucleotide

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CGP 69846A; CLUSTERIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GENE EXPRESSION MODULATOR 231; GTI 2040; INX 3001; ISIS 2503; ISIS 3521; ISOENZYME; MG 98; OBLIMERSEN; OGX 011; PROTEIN; PROTEIN BCL 2; PROTEIN HA RAS; PROTEIN KINASE C ALPHA; PROTEOME; RAF PROTEIN; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CANCER CHEMOTHERAPY; CANCER GENETICS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE THERAPY; GENOME; HUMAN; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN FAMILY;

EID: 0038688782     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00147-8     Document Type: Conference Paper

References (48)

1. Jansen B., Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol. 3:2002;672-683.
2. Paterson B.M., Roberts B.E., Kuff E.L. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. USA. 74:1977;4370-4374.
3. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 75:1978;280-284.
4. Ho P.T.C., Parkinson D.R. Antisense oligonucleotidesas therapeutics for malignant diseases. Semin. Oncol. 24:1997;187-202.
5. Crooke S.T. Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev. 8:1998;133-134.
6. Martin P. A new access to 2′-O-alkylated ribonucleosides and properties of 2′-O-alkylated oligoribonucleotides. Helvetica Chim. Acta. 78:1995;486-504.
7. Wahlestedt C., Salmi P., Good L., et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl. Acad. Sci. USA. 97:2000;5633-5638.
8. Monia B.P., Lesnik E.A., Gonzalez C., Lima W.F., McGee D., Guinosso C.J., et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:1993;14514-14522.
9. Mathews D.H., Sabina J., Zuker M., Turner D.H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 288:1999;911-940.
10. Milner N., Mir K.U., Southern E.M. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol. 15:1997;537-541.
11. Tu G.C., Cao Q.N., Zhou F., Israel Y. Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design. J. Biol. Chem. 273:1998;25125-25131.
12. Cotter F.E. Antisense therapy of hematologic malignancies. Semin. Hematol. 36:1999;9-14.
13. Waters J.S., Webb A., Cunningham D., et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18:2000;1812-1823.
14. Persidis A. Antisense therapeutics. Nat. Biotechnol. 17:1999;403-404.
15. Newton A.C. Reguation of protein kinase C. Curr. Opin. Cell. Biol. 9:1997;161-167.
16. Geiger T., Muller M., Dean N.M., Fabbro D. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des. 13:1998;35-45.
17. Yuen A.R., Halsey J., Fisher G.A., et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5:1999;3357-3363.
18. Yuen A., Advani R., Fisher G., et al. A phase I/II trial of ISIS 3521, an antisense inhibotro of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer. Am. Soc. Clin. Oncol. 19:2000;167.
19. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
20. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 226:1984;1097-1099.
21. Ziegler A., Luedke G.H., Fabbro D., Altmann K.H., Stahel R.A., Zangemeister-Wittke U. A novel antisense oligonucleotide targeting the coding region of the bcl-2 mRNA is a potent inducer of apoptosis in small cell lung cancer cells. J. Natl. Cancer Inst. 89:1997;1027-1036.
22. Zangemeister-Wittke U., Schenker T., Luedke G.H., Stahel R.A. Synergistic cytotoxicity of bcl-2 antisense and etoposide, doxorubicin and cisplatin in small cell lung cancer cells. Br. J. Cancer. 78:1998;1035-1042.
23. Jansen B., Wacheck V., Heere-Ress E., et al. Chemosensitisation of malignant melanoma by bcl-2 antisense therapy. Lancet. 356:2000;1728-1733.
24. Leech S.H., Olie R.A., Gautschi O., et al. Induction of apoptosis in lung cancer cells following bcl-xL antisense treatment. Int. J. Cancer. 86:2000;570-576.
25. Simoes-Wust A., Schürpf T., Hall J., Stahel R.A., Zangemeister-Wittke U. bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 76:2002;157-166.
26. Taylor J.K., Zhang Q.Q., Wyatt J.R., Dean N.M. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17:1999;1097-1100.
27. Miyake H., Monia B.P., Gleave M.E. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int. J. Cancer. 86:2000;855-862.
28. Gautschi O., Tschopp S., Olie R.A., et al. Activity of a novel bcl-2/bcl-xL bispecific antisense oligonucleotide against tumors of diverse histological origins. J. Natl. Cancer Inst. 93:2001;463-471.
29. Zangemeister-Wittke U., Leech S.H., Olie R.A., et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6:2000;2547-2555.
30. Moulding D.A., Giles R.V., Spiller D.G., White M.R., Tidd D.M., Edwards S.W. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood. 6:2000;1756-1763.
31. Thallinger C, Wolschek MF, Wacheck V, et al. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model, J Invest Dermatol, in press.
32. Howe L.R., Leevers S.J., Gomez N., Nakielny S., Cohen P., Marshall C.J. Activation of the MAP kinase pathway by the protein kinase raf. Cell. 71:1992;335-642.
33. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:1996;668-675.
34. Stevenson J.P., Yao K.S., Gallagher M., Friedland D., Mitchell E.P., Cassella A., et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17:1999;2227-2236.
35. Cunningham C.C., Holmlund J.T., Schiller J.H., Geary R.S., Kwoh T.J., Dorr A., et al. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 6:2000;1626-1631.
36. Oza A.M., Eisenhauer E., Swenerton K., et al. Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients with recurrent ovarian cancer. Clin. Cancer Res. 6:(Suppl.):2000;4572.
37. Cowsert L.M. In vitro and in vivo activity of antisense inhibitors of ras: potential for clinical development. Anticancer Drug Des. 12:1997;359-371.
38. Monia B.P., Johnston J.F., Ecker D.J., et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267:1992;19954-19962.
39. Gordon MS, Sandler AB, Holmlund TJ et al. Phase I trial of ISIS 2503, an antisense inhibitor of Ha-ras, administered by a 24-h weekly infusion to patients with advanced cancer. Presented at the 35th annual meeting of the American Society of Clinical Oncology, Atlanta, GA, 1999.
40. Bradbury A.W., Carter D.C., Miller W.R., Cho-Chung Y.S., Clair T. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br. J. Cancer. 69:1994;738-742.
41. Tortora G., Bianco R., Damiano V., et al. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin. Cancer Res. 6:2000;2506-2512.
42. Chen. H, Ness E, Marshall J et al. Phase I trial of a second-generation oligonucleotide (GEM231) targeted at type I protein kinase A in patients with refractory solid tumors. Presented at the 35th annual meeting of the American Society of Clinical Oncology, Atlanta, GA, 1999.
43. July L.V., Akbari M., Zellweger T., Jones E.C., Goldenberg S.L., Gleave M.E. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate. 50:2002;179-188.
44. Zellweger T., Miyake H., July L.V., Akbari M., Kiyama S., Gleave M.E. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia. 3:2001;360-367.
45. Deveraux Q.L., Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev. 13:1999;239-252.
46. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer. 3:2003;46-54.
47. Olie R.A., Simoes-Wust A.P., Baumann B., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60:2000;2805-2809.
48. Jaattela M. Heat shock proteins as cellular lifeguards. Ann. Med. 31:1999;261-271.